At the crossroad between transformation and tumor suppression

Cell Cycle

Volumn 8, Issue 1, 2009, Pages 49-57

  Bertini, Efrem ^a   Oka, Tsutomu ^b   Sudol, Marius ^b,c   Strano, Sabrina ^a   Blandino, Giovanni ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b WEIS CENTER FOR RESEARCH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Domain; Hippo pathway; Post translational modifications PTM; Transcription; Transformation; Tumor suppression; Yap

Indexed keywords

ABELSON KINASE; BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN U; PDZ PROTEIN; PROTEIN EBP50; PROTEIN KINASE B; PROTEIN KINASE YES; PROTEIN LATS1; PROTEIN P53; PROTEIN P53BP2; PROTEIN P73; PROTEIN SERINE THREONINE KINASE; PROTEIN TEAD1; PROTEIN TEAD2; PROTEIN TEAD3; PROTEIN TEAD4; SMAD7 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFE2; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WW DOMAIN BINDING PROTEIN 1; WW DOMAIN BINDING PROTEIN 2; YES ASSOCIATED PROTEIN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; DROSOPHILA; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; ORGAN GROWTH; ORGAN SIZE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; CHEMISTRY; METABOLISM;

MAMMALIA;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; HUMANS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 60749112337     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.1.7259     Document Type: Review

References (64)

1. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the yes proto-oncogene product. Oncogene 1994; 9:2145-52.
2. Sudol M, Bork P, Einbond A, Kastury K, Druck T, Negrini M, Huebner K, Lehman D. Characterization of the mammalian YAP (yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem 1995; 270:14733-41.
3. Bork P, Sudol M. The WW domain: A signalling site in dystrophin? Trends Biochem Sci 1994; 19:531-3.
4. Sudol M, Hunter T. NeW Wrinkles for an old domain. Cell 2000; 103:1001-4.
5. Espanel X, Sudol M. A single point mutation in a group I WW domain shifts its specificity to that of group II WW domains. J Biol Chem 1999; 274:17284-9.
6. Chen HI, Sudol M. The WW domain of yes-associated protein binds a proline-rich ligand that differs from the consensus established for src homology 3-binding modules. Proc Natl Acad Sci USA 1995; 92:7819-23.
7. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003; 278:33334-41.
8. Omerovic J, Puggioni EM, Napoletano S, Visco V, Fraioli R, Frati L, Gulino A, Alimandi M. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 2004; 294:469-79.
9. Ferrigno O, Lallemand F, Verrecchia F, L'Hoste S, Camonis J, Atfi A, Mauviel A. Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGFbeta/Smad signaling. Oncogene 2002; 21:4879-84.
10. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999; 18:2551-62.
11. Miller FD, Kaplan DR. To die or not to die: Neurons and p63. Cell Cycle 2007; 6:312-7.
12. Lanza M, Marinari B, Papoutsaki M, Giustizieri ML, D'Alessandra Y, Chimenti S, Guerrini L, Costanzo A. Cross-talks in the p53 family: DeltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants. Cell Cycle 2006; 5:1996-2004.
13. Rocco JW, Ellisen LW. p63 and p73: Life and death in squamous cell carcinoma. Cell Cycle 2006; 5:936-40.
14. D'Erchia AM, Tullo A, Lefkimmiatis K, Saccone C, Sbisa E. The fatty acid synthase gene is a conserved p53 family target from worm to human. Cell Cycle 2006; 5:750-8.
15. Sbisa E, Mastropasqua G, Lefkimmiatis K, Caratozzolo MF, D'Erchia AM, Tullo A. Connecting p63 to cellular proliferation: The example of the adenosine deaminase target gene. Cell Cycle 2006; 5:205-12.
16. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C, Vousden KH. p73 induces apoptosis via PUMA transactivation and bax mitochondrial translocation. J Biol Chem 2004; 279:8076-83.
17. Dobbelstein M, Strano S, Roth J, Blandino G. p73-induced apoptosis: A question of compartments and cooperation. Biochem Biophys Res Commun 2005; 331:688-93.
18. Bell HS, Ryan KM. Targeting the p53 family for cancer therapy: 'big brother' joins the fight. Cell Cycle 2007; 6:1995-2000.
19. Rother K, Li YY, Tschop K, Kirschner R, Muller GA, Mossner J, Engeland K. Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73. Cell Cycle 2007; 6:853-62.
20. Strano S, Blandino G. p73-mediated chemosensitivity: A preferential target of oncogenic mutant p53. Cell Cycle 2003; 2:348-9.
21. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M, Blandino G. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000; 275:29503-12.
22. Marin MC, Kaelin WG Jr. p63 and p73: Old members of a new family. Biochim Biophys Acta 2000; 1470:93-100.
23. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19:1438-49.
24. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G, Blandino G. Physical interaction with yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001; 276:15164-73.
25. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, Blandino G. The transcriptional coactivator yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol Cell 2005; 18:447-59.
26. Levy D, Adamovich Y, Reuven N, Shaul Y. The yes-associated protein 1 stabilizes p73 by preventing itch-mediated ubiquitination of p73. Cell Death Differ 2007; 14:743-51.
27. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH, Cesareni G, Melino G. The ubiquitin-protein ligase itch regulates p73 stability. EMBO J 2005; 24:836-48.
28. Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 2005; 19:316-21.
29. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11:11-23.
30. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21:2747-61.
31. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D. Elucidation of a universal size-control mechanism in drosophila and mammals. Cell 2007; 130:1120-33.
32. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283:5496-509.
33. Oka T, Mazack V, Sudol M. Mst2 and lats kinases regulate apoptotic function of YAP. J Biol Chem 2008; 283:27534-46.
34. Mah AS, Elia AE, Devgan G, Ptacek J, Schutkowski M, Snyder M, Yaffe MB, Deshaies RJ. Substrate specificity analysis of protein kinase complex Dbf2-Mob1 by peptide library and proteome array screening. BMC Biochem 2005; 6:22.
35. Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, Lian JB, Stein GS. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004; 23:790-9.
36. Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 2008; 29:350-61.
37. Pan D. Hippo signaling in organ size control. Genes Dev 2007; 21:886-97.
38. Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. The drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev 1995; 9:534-46.
39. Harvey K, Tapon N. The salvador-warts-hippo pathway-an emerging tumour-suppressor network. Nat Rev Cancer 2007; 7:182-91.
40. Bothos J, Tuttle RL, Ottey M, Luca FC, Halazonetis TD. Human LATS1 is a mitotic exit network kinase. Cancer Res 2005; 65:6568-75.
41. Yang X, Yu K, Hao Y, Li DM, Stewart R, Insogna KL, Xu T. LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1. Nat Cell Biol 2004; 6:609-17.
42. Toji S, Yabuta N, Hosomi T, Nishihara S, Kobayashi T, Suzuki S, Tamai K, Nojima H. The centrosomal protein Lats2 is a phosphorylation target of aurora-A kinase. Genes Cells 2004; 9:383-97.
43. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 2006; 20:2687-700.
44. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S, Taubert H, Dammann R. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007; 46:865-71.
45. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S. Downregulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005; 11:1380-5.
46. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G, Lu D. Promoter hypermethylation-mediated downregulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006; 56:450-8.
47. Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D, Baccarini M, Vass JK, Kolch W, O'neill E. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 2007; 27:962-75.
48. Praskova M, Xia F, Avruch J. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol 2008; 18:311-21.
49. Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the drosophila hippo pathway. Cancer Res 2008; 68:2789-94.
50. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125:1253-67.
51. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103:12405-10.
52. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17:2054-60.
53. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28:2426-36.
54. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005; 309:1074-8.
55. Hong JH, Yaffe MB. TAZ: A beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 2006; 5:176-9.
56. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW, Wrana JL. TAZ controls smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008; 10:837-48.
57. Silvia Di Agostino, Giancarlo Cortese, Olimpia Monti, Stefania Dell'Orso, Ada Sacchi, Miriam Eisenstein, Gennaro Citro, Sabrina Strano and Giovanni Blandino. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle 2008; 21.
58. Oka T and Sudol M. Duality of YAP: an Oncogene and the Promoter of Apoptosis. In: Adaptor Proteins and Cancer. (Editor: M. Georgescu), Transworld Research Network 2008; 209-18.
59. Kawahara M, Hori T, Oka T, Sudol M and Uchiyama T. Kpm-Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 2008.
60. Gavva NR, Gavva R, Ermekova K, Sudol M, Shen CJ. Interaction of WW domains with hematopoietic transcription factor p45/NF-E2 and RNA polymerase II. J Biol Chem 1997; 272:24105-8.
61. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-abl and p73alpha and their collaboration to induce apoptosis. Nature 1999; 399:809-13.
62. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001; 15:1229-41.
63. Mohler PJ, Kreda SM, Boucher RC, Sudol M, Stutts MJ, Milgram SL. Yes-associated protein 65 localizes p62(c-yes) to the apical compartment of airway epithelia by association with EBP50. J Cell Biol 1999; 147:879-90.
64. Howell M, Borchers C, Milgram SL. Heterogeneous nuclear ribonuclear protein U associates with YAP and regulates its co-activation of bax transcription. J Biol Chem 2004; 279:26300-6.